Artemisia afra infusions clinical benefits as a complementary treatment to “WHO” approved drugs against tuberculosis

2024-09-16 | Télécharger

BACKGROUND :

In the past few years, the number of people infected with pulmonary tuberculosis has increased. Today, it kills thousands in Africa alone, millions worldwide and the numbers keep on increasing due to COVID-19 (WHO, 2021). Moreover, resistance to conventional anti tuberculosis recommended drugs is increasing thus rendering more and more difficult to treat this deadly disease. Currently, one third of the world population is infected with various forms of TB, and each year 2-3 million people of the world die from TB infection or its complications. Based on an estimate, nearly one billion people were affected by the disease between 2000 and 2020.

a. It has been very interesting to notice the rapid improvement of the patients both clinically and Para clinically with the improved laboratory parameters (ESR, CRP, Sputum smear).
b. The results are very encouraging and could be a basis to conduct Randomized Clinical Trial and develop a cheap herbal treatment supplement and with less side effects or toxicities.
c. The authors suggest that the next phase of the study will be a comparison of 50 patients on the WHO approved treatment ALONE versus 50 patients on Artemisia Afra and WHO drugs.
d. These novel antimycobacterial results and the advanced synergistic activity observed for the Artemisia afra infusion present an opportunity to establish a new and cheap way to address resistant tuberculosis and to speed up recovery for regular tuberculosis with no side effects.